
## Timothy Cundy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9522647/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Impact of Bariatric Surgery on Unplanned Hospital Admissions for Infection. Obesity Surgery, 2022, 32, 1896-1901.	2.1	2
2	Early Worsening of Diabetic Nephropathy in Type 2 Diabetes After Rapid Improvement in Chronic Severe Hyperglycemia. Diabetes Care, 2021, 44, e55-e56.	8.6	16
3	Response to Comment on Cundy et al. Early Worsening of Diabetic Nephropathy in Type 2 Diabetes After Rapid Improvement in Chronic Severe Hyperglycemia. Diabetes Care 2021;44:e55–e56. Diabetes Care, 2021, 44, e112-e112.	8.6	2
4	Socioeconomic status and risk factors for complications in young people with type 1 or type 2 diabetes: a cross-sectional study. BMJ Open Diabetes Research and Care, 2021, 9, e002485.	2.8	5
5	Juvenile Paget's disease with compound heterozygous mutations in TNFRSF11B presenting with recurrent clavicular fractures and a mild skeletal phenotype. Bone, 2020, 130, 115098.	2.9	3
6	Bisphosphonateâ€Induced Deterioration of Osteomalacia in Undiagnosed Adult Fanconi Syndrome. JBMR Plus, 2020, 4, e10374.	2.7	8
7	Insulin use and new diabetes after acceptance for bariatric surgery: comparison of outcomes after completion of surgery or withdrawal from the program. BMJ Open Diabetes Research and Care, 2020, 8, e001837.	2.8	4
8	Bisphosphonate Use and Fractures in Adults with Hypophosphatasia. JBMR Plus, 2019, 3, e10223.	2.7	16
9	Evidence of a Media-Induced Nocebo Response Following a Nationwide Antidepressant Drug Switch. Clinical Psychology in Europe, 2019, 1, .	1.1	17
10	Mutations That Alter the Carboxy-Terminal-Propeptide Cleavage Site of the Chains of Type I Procollagen Are Associated With a Unique Osteogenesis Imperfecta Phenotype. Journal of Bone and Mineral Research, 2018, 33, 1260-1271.	2.8	21
11	Juvenile Paget disease. Metabolism: Clinical and Experimental, 2018, 80, 15-26.	3.4	32
12	Attrition after Acceptance onto a Publicly Funded Bariatric Surgery Program. Obesity Surgery, 2018, 28, 2500-2507.	2.1	25
13	Paget's disease of bone. Metabolism: Clinical and Experimental, 2018, 80, 5-14.	3.4	58
14	Long-Term Effects of Intravenous Ibandronate in Paget's Disease of Bone. Calcified Tissue International, 2017, 100, 250-254.	3.1	8
15	<b>Treating</b> Paget's Disease—Why and How Much?. Journal of Bone and Mineral Research, 2017, 32, 1163-1164.	2.8	8
16	Severe proton pump inhibitorâ€induced hypomagnesaemia in a mother and daughter. Internal Medicine Journal, 2017, 47, 341-342.	0.8	3
17	Presentation, pathology and prognosis of renal disease in type 2 diabetes. BMJ Open Diabetes Research and Care, 2017, 5, e000412.	2.8	33
18	Durability of Response to Zoledronate Treatment and Competing Mortality in Paget's Disease of Bone. Journal of Bone and Mineral Research, 2017, 32, 753-756.	2.8	33

#	Article	IF	CITATIONS
19	Clinical Perspectives of Paget's Disease of Bone. , 2016, , 1-14.		О
20	Reversible Deterioration in Hypophosphatasia Caused by Renal Failure With Bisphosphonate Treatment. Journal of Bone and Mineral Research, 2015, 30, 1726-1737.	2.8	48
21	Evolution of Paget's disease of bone in adults inheriting <i><scp>SQSTM</scp>1</i> mutations. Clinical Endocrinology, 2015, 83, 315-319.	2.4	26
22	Authors' reply to Hodson and colleagues. BMJ, The, 2014, 348, g2692-g2692.	6.0	0
23	The Link between Health Complaints and Wind Turbines: Support for the Nocebo Expectations Hypothesis. Frontiers in Public Health, 2014, 2, 220.	2.7	31
24	Gestational diabetes: new criteria may triple the prevalence but effect on outcomes is unclear. BMJ, The, 2014, 348, g1567-g1567.	6.0	122
25	Novel homozygous mutations in the osteoprotegerin gene TNFRSF11B in two unrelated patients with juvenile Paget's disease. Bone, 2014, 68, 6-10.	2.9	18
26	Republished: Paget's disease of bone: clinical review and update. Postgraduate Medical Journal, 2014, 90, 328-331.	1.8	1
27	Proteinuric renal disease in type 2 diabetes—Is remission of proteinuria associated with improved mortality and morbidity?. Diabetes Research and Clinical Practice, 2014, 103, 63-70.	2.8	8
28	The power of positive and negative expectations to influence reported symptoms and mood during exposure to wind farm sound Health Psychology, 2014, 33, 1588-1592.	1.6	56
29	Obstetric interventions for women with type 1 or type 2 diabetes. International Journal of Gynecology and Obstetrics, 2013, 123, 50-53.	2.3	7
30	The Effect of an Apparent Change to a Branded or Generic Medication on Drug Effectiveness and Side Effects. Psychosomatic Medicine, 2013, 75, 90-96.	2.0	75
31	Establishing Consensus in the Diagnosis of Gestational Diabetes Following HAPO: Where Do We Stand?. Current Diabetes Reports, 2013, 13, 43-50.	4.2	29
32	Tumoral Calcinosis in a Patient on Peritoneal Dialysis. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1799-1799.	3.6	0
33	Paget's disease of bone: clinical review and update. Journal of Clinical Pathology, 2013, 66, 924-927.	2.0	47
34	Low-dose Fluoride in Postmenopausal Women: A Randomized Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2301-2307.	3.6	20
35	Mutations in FKBP10, which result in Bruck syndrome and recessive forms of osteogenesis imperfecta, inhibit the hydroxylation of telopeptide lysines in bone collagen. Human Molecular Genetics, 2013, 22, 1-17.	2.9	135
36	Bone Density Testing in Older Women. JAMA - Journal of the American Medical Association, 2012, 308, 1428.	7.4	1

#	Article	IF	CITATIONS
37	Impact of television coverage on the number and type of symptoms reported during a health scare: a retrospective pre–post observational study. BMJ Open, 2012, 2, e001607.	1.9	64
38	Paget's disease of bone. Clinical Biochemistry, 2012, 45, 43-48.	1.9	38
39	Reprint: Paget's disease of bone. Clinical Biochemistry, 2012, 45, 970-975.	1.9	12
40	Recent Advances in Osteogenesis Imperfecta. Calcified Tissue International, 2012, 90, 439-449.	3.1	88
41	Paget's disease in patients of Asian descent in New Zealand. Journal of Bone and Mineral Research, 2012, 27, 223-226.	2.8	23
42	Proton pump inhibitors and severe hypomagnesaemia. Current Opinion in Gastroenterology, 2011, 27, 180-185.	2.3	89
43	Genome-wide association identifies three new susceptibility loci for Paget's disease of bone. Nature Genetics, 2011, 43, 685-689.	21.4	158
44	Familial Paget Disease and SQSTM1 Mutations in New Zealand. Calcified Tissue International, 2011, 89, 258-264.	3.1	13
45	1,25-Dihydroxyvitamin D3 Hypersensitivity of Osteoclast Precursors from Patients with Paget's Disease. Journal of Bone and Mineral Research, 2010, 15, 228-236.	2.8	81
46	Response to publication of PRISM trial. Journal of Bone and Mineral Research, 2010, 25, 1463-1464.	2.8	9
47	Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget's disease of bone. Nature Genetics, 2010, 42, 520-524.	21.4	258
48	Ocular Manifestations of Juvenile Paget Disease. JAMA Ophthalmology, 2010, 128, 698.	2.4	29
49	Skeletal phenotype of mandibuloacral dysplasia associated with mutations in ZMPSTE24. Bone, 2010, 47, 591-597.	2.9	31
50	Paget's disease of bonebecoming a rarity?. Rheumatology, 2009, 48, 1232-1235.	1.9	46
51	Advances in the molecular pharmacology and therapeutics of bone disease and international symposium on paget's disease. IBMS BoneKEy, 2009, 6, 439-445.	0.0	0
52	Absence of Somatic SQSTM1 Mutations in Paget's Disease of Bone. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 691-694.	3.6	31
53	Osteonecrosis of the jaw. Skeletal Radiology, 2009, 38, 5-9.	2.0	44
54	Thyroxine: anatomy of a health scare. BMJ: British Medical Journal, 2009, 339, b5613-b5613.	2.3	56

#	Article	IF	CITATIONS
55	Paget's disease of bone. Expert Review of Endocrinology and Metabolism, 2009, 4, 651-668.	2.4	6
56	Identification of a Major Locus for Paget's Disease on Chromosome 10p13 in Families of British Descent. Journal of Bone and Mineral Research, 2008, 23, 58-63.	2.8	47
57	Paget disease of bone. Trends in Endocrinology and Metabolism, 2008, 19, 246-253.	7.1	52
58	Pregnancy loss and neonatal death in women with type 1 or type 2 diabetes mellitus. Insulin, 2008, 3, 167-175.	0.2	11
59	Failure to Detect Measles Virus Ribonucleic Acid in Bone Cells from Patients with Paget's Disease. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1398-1401.	3.6	60
60	Addition of Monofluorophosphate to Estrogen Therapy in Postmenopausal Osteoporosis: A Randomized Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2446-2452.	3.6	21
61	Ethnic differences in illness perceptions, self-efficacy and diabetes self-care. Psychology and Health, 2007, 22, 787-811.	2.2	92
62	Bone Formation Markers in Adults with Mild Osteogenesis Imperfecta. Clinical Chemistry, 2007, 53, 1109-1114.	3.2	22
63	Differing Causes of Pregnancy Loss in Type 1 and Type 2 Diabetes. Diabetes Care, 2007, 30, 2603-2607.	8.6	72
64	Delayed Development of Paget's Disease in Offspring InheritingSQSTM1Mutations. Journal of Bone and Mineral Research, 2007, 22, 411-415.	2.8	73
65	Recovery From Skeletal Fluorosis. Journal of Bone and Mineral Research, 2007, 22, 1475-1475.	2.8	7
66	Is the Prevalence of Paget's Disease of Bone Decreasing?. Journal of Bone and Mineral Research, 2006, 21, P9-P13.	2.8	44
67	Evaluation of the role of Valosin-containing protein in the pathogenesis of familial and sporadic Paget's disease of bone. Bone, 2006, 38, 280-285.	2.9	38
68	Depot Medroxyprogesterone Acetate and Bone Mineral Density in Adolescents—The Black Box Warning: A Position Paper of the Society for Adolescent Medicine. Journal of Adolescent Health, 2006, 39, 296-301.	2.5	127
69	Peak Bone Mass After Exposure to Antenatal Betamethasone and Prematurity: Follow-up of a Randomized Controlled Trial. Journal of Bone and Mineral Research, 2006, 21, 1175-1186.	2.8	45
70	Differential Gene Expression in Cultured Osteoblasts and Bone Marrow Stromal Cells From Patients With Paget's Disease of Bone. Journal of Bone and Mineral Research, 2006, 22, 298-309.	2.8	76
71	Recombinant Osteoprotegerin for Juvenile Paget's Disease. New England Journal of Medicine, 2005, 353, 918-923.	27.0	89
72	Insulin Sensitivity in the Offspring of Women With Type 1 and Type 2 Diabetes. Diabetes Care, 2004, 27, 1148-1152.	8.6	53

#	Article	IF	CITATIONS
73	Treatment of Idiopathic Hyperphosphatasia With Intensive Bisphosphonate Therapy. Journal of Bone and Mineral Research, 2004, 19, 703-711.	2.8	51
74	Novel UBA Domain Mutations of SQSTM1 in Paget's Disease of Bone: Genotype Phenotype Correlation, Functional Analysis, and Structural Consequences. Journal of Bone and Mineral Research, 2004, 19, 1122-1127.	2.8	142
75	Role of TAFII-17, a VDR Binding Protein, in the Increased Osteoclast Formation in Paget's Disease. Journal of Bone and Mineral Research, 2004, 19, 1154-1164.	2.8	49
76	Susceptibility to Paget's Disease of Bone Is Influenced by a Common Polymorphic Variant of Osteoprotegerin. Journal of Bone and Mineral Research, 2004, 19, 1506-1511.	2.8	59
77	Ubiquitin-Associated Domain Mutations of SQSTM1 in Paget's Disease of Bone: Evidence for a Founder Effect in Patients of British Descent. Journal of Bone and Mineral Research, 2004, 20, 227-231.	2.8	45
78	Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone. Bone, 2004, 35, 224-230.	2.9	99
79	Vitamin D antagonist, TEI-9647, inhibits osteoclast formation induced by 1α,25-dihydroxyvitamin D3 from pagetic bone marrow cells. Journal of Steroid Biochemistry and Molecular Biology, 2004, 89-90, 331-334.	2.5	27
80	Idiopathic Hyperphosphatasia andTNFRSF11BMutations: Relationships Between Phenotype and Genotype. Journal of Bone and Mineral Research, 2003, 18, 2095-2104.	2.8	113
81	The deleted in colorectal carcinoma (DCC) gene 201 R → G polymorphism: no evidence for genetic association with autoimmune disease. European Journal of Human Genetics, 2003, 11, 840-844.	2.8	2
82	A Randomized Controlled Trial of Estrogen Replacement Therapy in Long-Term Users of Depot Medroxyprogesterone Acetate. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 78-81.	3.6	82
83	Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. Human Molecular Genetics, 2002, 11, 2735-2739.	2.9	307
84	A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Human Molecular Genetics, 2002, 11, 2119-2127.	2.9	190
85	Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception. American Journal of Obstetrics and Gynecology, 2002, 186, 978-983.	1.3	58
86	Sequence Analysis of Measles Virus Nucleocapsid Transcripts in Patients with Paget's Disease. Journal of Bone and Mineral Research, 2002, 17, 145-151.	2.8	95
87	Genomewide Search in Familial Paget Disease of Bone Shows Evidence of Genetic Heterogeneity with Candidate Loci on Chromosomes 2q36, 10p13, and 5q35. American Journal of Human Genetics, 2001, 69, 1055-1061.	6.2	113
88	LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development. Cell, 2001, 107, 513-523.	28.9	2,055
89	Osteoporosis pseudoglioma syndrome: Treatment of spinal osteoporosis with intravenous bisphosphonates. Journal of Pediatrics, 2000, 137, 410-415.	1.8	47
90	Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone. Journal of Clinical Investigation, 2000, 105, 1833-1838.	8.2	142

#	Article	IF	CITATIONS
91	Measles virus nucleocapsid transcript expression is not restricted to the osteoclast lineage in patients with Paget's disease of bone. Experimental Hematology, 1999, 27, 1528-1532.	0.4	37
92	The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clinical Endocrinology, 1998, 49, 615-618.	2.4	88
93	Spinal bone density in women using depot medroxyprogesterone contraception*1. Obstetrics and Gynecology, 1998, 92, 569-573.	2.4	86
94	Spinal Bone Density in Women Using Depot Medroxyprogesterone Contraception. Obstetrics and Gynecology, 1998, 92, 569-573.	2.4	39
95	Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial. American Journal of Medicine, 1996, 101, 341-348.	1.5	164
96	Medroxyprogesterone acetate enhances the spinal bone mineral density response to oestrogen in late post-menopausal women. Clinical Endocrinology, 1996, 44, 293-296.	2.4	44
97	Sources of interracial variation in bone mineral density. Journal of Bone and Mineral Research, 1995, 10, 368-373.	2.8	100
98	Glomerular hyperfiltration in young Polynesians with type 2 diabetes. Diabetes Research and Clinical Practice, 1994, 25, 155-160.	2.8	15
99	Osteomalacia after pamidronate for Paget's disease. Lancet, The, 1994, 343, 855.	13.7	4
100	Fetal liver length in diabetic pregnancy. American Journal of Obstetrics and Gynecology, 1994, 170, 1308-1312.	1.3	25
101	Fetal liver length in diabetic pregnancy. American Journal of Obstetrics and Gynecology, 1994, 170, 1308-1312.	1.3	23
102	Determinants of Birth-weight in Women with Established and Gestational Diabetes. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1993, 33, 249-254.	1.0	30
103	Rapid suppression of plasma alkaline phosphatase activity after renal transplantation in patients with osteodystrophy. Clinica Chimica Acta, 1987, 164, 285-291.	1.1	15
104	Referrals to Psychiatrists in a General Hospital — Comparison of Two Methods of Liaison Psychiatry: Preliminary Communication. Journal of the Royal Society of Medicine, 1985, 78, 463-468.	2.0	37